1月7日，百龙创园跌5.16%，截至发稿，报20.95元/股，成交1.02亿元，换手率1.14%，总市值87.99亿 元。 资料显示，山东百龙创园生物科技股份有限公司位于山东省德州(禹城)国家高新技术产业开发区德信大 街，成立日期2005年12月30日，上市日期2021年4月21日，公司主营业务涉及益生元系列产品、膳食纤 维系列产品、其他淀粉糖(醇)系列产品和健康甜味剂产品的研发、生产及销售。主营业务收入构成为： 膳食纤维系列54.15%，益生元系列28.00%，健康甜味剂13.57%，其他(补充)3.91%，其他淀粉糖 (醇)0.38%。 截至发稿，孙文龙累计任职时间10年353天，现任基金资产总规模22.44亿元，任职期间最佳基金回报 238.74%， 任职期间最差基金回报-2.98%。 从基金十大重仓股角度 数据显示，博道基金旗下1只基金重仓百龙创园。博道惠泰优选混合A（016840）三季度增持12.19万 股，持有股数487.99万股，占基金净值比例为4.36%，位居第四大重仓股。根据测算，今日浮亏损失约 556.31万元。 从百龙创园十大流通股东角度 数据显示，博道基金旗下1只基金位居百龙创园十大流 ...

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank, as well as the depreciation of the RMB [2][3][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic products, dietary fiber products, other starch sugar (alcohol) products, and health sweeteners [8]. - The revenue composition of the company includes dietary fiber series (54.15%), prebiotic series (28.00%), health sweeteners (13.57%), and others (3.91%) [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%, and a net profit attributable to the parent company of 265 million yuan, with a year-on-year increase of 44.93% [9]. - The company has distributed a total of 204 million yuan in dividends since its A-share listing, with 193 million yuan in the last three years [10]. Group 3: Market Position and Recognition - The company is recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [4]. - The company has established good cooperative relationships with numerous well-known domestic and international enterprises, accumulating a large number of quality customer resources [4]. Group 4: Stock Performance and Investor Activity - The stock price of Bailong Chuangyuan increased by 1.16% on January 5, with a trading volume of 144 million yuan and a turnover rate of 1.56%, leading to a total market capitalization of 9.177 billion yuan [1]. - As of December 19, the number of shareholders in Bailong Chuangyuan was 11,600, a decrease of 5.87% from the previous period, with an average of 36,348 circulating shares per person, an increase of 6.23% [9].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing positive market movements, with a recent stock price increase and significant revenue growth, driven by its innovative health sweetener products and strategic investments in the banking sector [1][8]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweetener products, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8]. - As of December 10, the company had 12,300 shareholders, an increase of 12.12% from the previous period, with an average of 34,216 circulating shares per shareholder, a decrease of 10.81% [8]. - The company was established on December 30, 2005, and went public on April 21, 2021, located in the Dezhou (Yucheng) National High-tech Industrial Development Zone [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%, and a net profit attributable to shareholders of 265 million yuan, up 44.93% year-on-year [8]. - The company has distributed a total of 204 million yuan in dividends since its A-share listing, with 193 million yuan distributed over the past three years [9]. Group 3: Market Position and Strategic Advantages - The company produces allulose, a rare monosaccharide that serves as a low-calorie alternative to sucrose, making it ideal for individuals with obesity and diabetes [2]. - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, benefiting from the depreciation of the RMB [3][4]. - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which enhances its competitiveness and stability within the industry [4]. Group 4: Stock Market Activity - On December 17, the company's stock rose by 2.68%, with a trading volume of 100 million yuan and a turnover rate of 1.14%, leading to a total market capitalization of 8.862 billion yuan [1]. - The average trading cost of the stock is 20.54 yuan, with the stock price approaching a resistance level of 21.24 yuan, indicating potential for upward movement if this level is surpassed [7].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized and innovative" enterprise. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fiber products, and healthy sweeteners, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8] - As of November 30, the company had 10,900 shareholders, a decrease of 18.48% from the previous period, with an average of 38,364 circulating shares per shareholder, an increase of 22.67% [8] - The company achieved a revenue of 969 million yuan in the first nine months of 2025, representing a year-on-year growth of 18.10%, and a net profit of 265 million yuan, up 44.93% year-on-year [8] Group 2: Market Position and Financials - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial stability [3] - The overseas revenue accounts for 60.62% of total revenue, benefiting from the depreciation of the RMB [4] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Investment Highlights - The company produces allulose, a rare monosaccharide that serves as a low-calorie alternative to sucrose, making it ideal for individuals with obesity and diabetes [2] - The company has been recognized as a "specialized and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong market focus and innovation capabilities [4] - The stock has seen a recent decline of 2.01% with a trading volume of 48.91 million yuan and a market capitalization of 8.61 billion yuan [1]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized and innovative" enterprise. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and healthy sweeteners, with a revenue composition of 54.15% from dietary fibers, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8] - As of October 31, the company had 13,400 shareholders, an increase of 3.75% from the previous period, with an average of 31,274 circulating shares per shareholder, a decrease of 3.62% [8] - The company was established on December 30, 2005, and went public on April 21, 2021 [8] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%, and a net profit attributable to shareholders of 265 million yuan, up 44.93% year-on-year [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Market Position and Strategic Advantages - The company produces allulose, a rare monosaccharide that serves as a low-calorie sugar substitute, making it ideal for individuals with obesity and diabetes [2] - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which enhances its financial positioning [3] - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the RMB [4] - The company has been recognized as a "specialized and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong market focus and innovation capabilities [4] Group 4: Stock Performance and Market Sentiment - On November 4, the company's stock fell by 1.02%, with a trading volume of 77.1354 million yuan and a turnover rate of 0.89%, resulting in a total market capitalization of 8.564 billion yuan [1] - The stock's average trading cost is 20.46 yuan, with the current price near a support level of 20.18 yuan, indicating potential volatility [7] - The main capital inflow for the day was negative at 2.5415 million yuan, with a continuous reduction in main capital over the past two days [5][6]

Group 1 - The core point of the article highlights the recent performance of Bailong Chuangyuan, which saw a 5.09% increase in stock price, reaching 20.44 CNY per share, with a total market capitalization of 8.585 billion CNY [1] - Bailong Chuangyuan specializes in the research, production, and sales of prebiotic products, dietary fiber products, starch sugar (alcohol) products, and health sweeteners, with dietary fiber contributing 54.15% to revenue, prebiotics 28.00%, health sweeteners 13.57%, and others 3.91% [1] - The company is located in Dezhou, Shandong Province, and was established on December 30, 2005, with its listing date on April 21, 2021 [1] Group 2 - From the perspective of major shareholders, Baodao Fund's Hui Tai You Xuan Mixed A Fund increased its holdings in Bailong Chuangyuan by 121,900 shares in the third quarter, now holding 4.8799 million shares, which is 1.16% of the circulating shares [2] - The fund has achieved a year-to-date return of 27.75% and ranks 3442 out of 8154 in its category, with a total fund size of 778 million CNY [2] - The fund manager, Sun Wenlong, has a tenure of 10 years and 285 days, with the best fund return during his tenure being 238.74% [3] Group 3 - Bailong Chuangyuan is the fourth largest holding in the Baodao Hui Tai You Xuan Mixed A Fund, accounting for 4.36% of the fund's net value [4] - The fund's estimated floating profit from its investment in Bailong Chuangyuan is approximately 4.8311 million CNY [4]

Core Viewpoint - Bailong Chuangyuan is a leading supplier of prebiotics and dietary fiber products in China, with a comprehensive industry chain advantage and multiple core technologies [1] Group 1: Business Performance - In Q3 2025, Bailong Chuangyuan reported revenue of 969 million yuan, ranking 16th in the industry, below the industry average of 3.571 billion yuan and median of 1.238 billion yuan [2] - The main business composition includes dietary fiber series at 624 million yuan (54.15%), prebiotic series at 322 million yuan (28.00%), and health sweeteners at 156 million yuan (13.57%) [2] - The net profit for the same period was 265 million yuan, ranking 7th in the industry, lower than the top two competitors but higher than the industry average of 539 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 27.16%, which is lower than the industry average of 28.46% [3] - The gross profit margin for Q3 2025 was 41.84%, higher than the industry average of 28.77% [3] Group 3: Executive Compensation - The chairman, Dou Baode, received a salary of 1.2093 million yuan in 2024, an increase of 478,100 yuan from 2023 [4] - The general manager, Zhao Hongjian, received a salary of 1.505 million yuan in 2024, an increase of 403,400 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.87% to 12,900 [5] - The average number of circulating A-shares held per shareholder decreased by 1.84% to 32,400 [5] Group 5: Future Outlook - Analysts expect continued revenue growth and net profit increases, with projected EPS for 2025-2027 at 0.85, 1.12, and 1.48 yuan respectively [5] - The opening of the domestic allulose market and the upcoming production capacity for sweeteners are anticipated to drive future growth [6]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank amid the depreciation of the RMB. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweetener products, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other sources [8] - As of August 29, the number of shareholders is 12,700, a decrease of 0.43%, while the average circulating shares per person increased by 0.43% to 33,056 shares [8] Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4] Group 4: Stock Performance - On October 21, the company's stock rose by 1.91%, with a trading volume of 62.88 million yuan and a turnover rate of 0.78%, leading to a total market capitalization of 8.08 billion yuan [1] - The average trading cost of the stock is 20.50 yuan, with a current support level at 19.05 yuan [7]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank, as well as the depreciation of the RMB [2][3][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and health sweeteners, with a revenue composition of 54.15% from dietary fibers, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8]. - As of August 29, the company had 12,700 shareholders, a decrease of 0.43% from the previous period, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8]. - The company was listed on April 21, 2021, and is classified under the basic chemical industry, specifically in food and feed additives [8]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3]. - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4]. Group 4: Stock Performance - On October 9, the company's stock rose by 2.54%, with a trading volume of 93.33 million yuan and a turnover rate of 1.09%, leading to a total market capitalization of 8.644 billion yuan [1]. - The average trading cost of the stock is 20.44 yuan, with the current price near a support level of 20.53 yuan, indicating potential for a rebound if this support holds [7].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank, as well as the depreciation of the RMB [2][3][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and health sweeteners, with a revenue composition of 54.15% from dietary fibers, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8]. - As of August 29, the company had 12,700 shareholders, a decrease of 0.43% from the previous period, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8]. - The company was established on December 30, 2005, and went public on April 21, 2021 [8]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3]. - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and innovation [4]. - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the RMB [4]. Group 4: Stock Performance and Trading Activity - On September 30, the company's stock rose by 0.20%, with a trading volume of 64.54 million yuan and a turnover rate of 0.77%, bringing the total market capitalization to 8.43 billion yuan [1]. - The average trading cost of the stock is 20.44 yuan, with the current price approaching a resistance level of 20.15 yuan, indicating potential for a price correction if this level is not surpassed [7]. - The main capital inflow for the day was 461,300 yuan, with no significant trends in capital movement observed [5][6].